Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of EGF in screening drugs used for diagnosing or treating implantation metastatic cancer

A metastatic cancer, VEGF-C technology, applied in the medical field, can solve the problem of unclear tumor cell survival sphere mechanism, and achieve the effect of promoting tumor cell proliferation and improving prognosis

Inactive Publication Date: 2017-03-15
广州道瑞医药科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, how freely detached tumor cells survive in the environment of implantation and metastasis and the mechanism of sphere formation at the initial stage of implantation and metastasis are still unclear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of EGF in screening drugs used for diagnosing or treating implantation metastatic cancer
  • Applications of EGF in screening drugs used for diagnosing or treating implantation metastatic cancer
  • Applications of EGF in screening drugs used for diagnosing or treating implantation metastatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] 1. Materials and methods

[0033] 1.1 Study Approval

[0034] All animal experiments were performed after institutional approval by the Yale University Animal Care Committee. Human tumor spheroids from patients with advanced (ie, stage III-IV) ovarian cancer were harvested from ascites fluid provided by informed consent patients, as performed at Yale University School of Medicine, New Haven, Connecticut (HIC protocol #1111003959). Clinical paraffin specimens were used after approval by the Ethical Review Committee of the Cancer Hospital Affiliated to Harbin Medical University, China.

[0035] 1.2 Animal model

[0036] All animal experiments were approved by the Yale University Animal Care Committee. All mice were of the C57BL / 6 series. Lysozyme Cre mice were crossed with tomato (mT / mG) mice to extract cells with the lineage marker lysozyme. Nude mice were purchased from Jackson Laboratory. Put 100ul mouse ovarian cancer ID8 or human ovarian cancer SKOV3 cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses applications of EGF in screening drugs used for diagnosing or treating implantation metastatic cancer, and belongs to the field of medicine. Close connection between tumor-associated macrophage (TAM) related globoid with ovarian cancer clinical pathology is confirmed; it is shown by an ovarian epithelial cancer mouse model that TAM is capable of promoting forming of the globoids and the growth of tumour in the early phase of ovarian cancer implantation metastasis; EGF secreted by TAM is capable of activating EGFR on tumor cells, and then the EGFR is capable of realizing up regulation of surrounding tumor cell VEGFs-VEGFRs channel signal transduction and promoting tumor cell proliferation and differentiation; EGF is capable of realizing up regulation of expression of alpha M beta2 integral protein on TAM and ICAM-1 on tumor cells, and promoting association of tumor cells-TAM. In mouse, removing of TAM and drug blocking EGFR or neutralizing of ICAM-1 with an antibody is capable of inhibiting forming of the globoid and ovarian cancer development. The invention discloses a new mechanism of TAM-mediated globoid forming, and providing a novel targeted therapy method for ovarian cancer and other remote metastatic cancers.

Description

technical field [0001] The invention relates to the application of EGF in screening drugs for diagnosing or treating implantation metastatic cancer, which belongs to the field of medicine. Background technique [0002] Ovarian cancer (OC) is the second most common tumor and one of the leading causes of death in gynecology in the United States. The high mortality rate is mainly due to the difficulty of diagnosing ovarian cancer at an early stage (I / II) until it spreads and progresses to an advanced stage (III / IV). We have reported that the diagnosis rates of OC patients from stage I to IV were 7.19%, 8.63%, 72% and 72.18%, respectively. The prognosis of OC patients is poor, and the average five-year survival rate of OC patients at various stages is 42%. After long-term follow-up observation of patients with stage III and stage IV, the five-year survival rate was found to be less than 10%. However, for patients diagnosed at an early stage (I-II), especially those whose tumo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/68G01N33/574A61K48/00A61K39/395A61K31/7088A61K31/517A61K31/5377A61P35/04
CPCC12Q1/6886A61K31/517A61K31/5377A61K31/7088A61K39/3955C12Q2600/136C12Q2600/158G01N33/57449G01N33/68G01N2333/485G01N2500/04
Inventor 王敏
Owner 广州道瑞医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products